Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston and Richmond, United StatesSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 110 people enrolled
- Started
- 17 Jul 2019
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 4 groups
- Treatments tested
- Haloperidol
- Lorazepam
- Placebo
- Quality-of-Life Assessment
- Questionnaire Administration
- Record updated
- 15 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- [Patients] Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease)
- [Patients] Admitted to the acute palliative care unit‡
- [Patients] Delirium as per DSM-5 criteria
- [Patients] Hyperactive or mixed delirium with RASS ≥1* in the past 24 h despite efforts to treat potential underlying causes
- [Patients] On scheduled haloperidol for delirium (≤8 mg in the past 24 h) or required ≥4 mg of rescue haloperidol for agitation in the past 24 h
- [Patients] Age 18 years or older
- [Caregivers] Patient's spouse, adult child, sibling, parent, other relative, or significant other (partner as defined by patient)
- [Caregivers] Age 18 years or older
Who cannot take part
- [Patients] History of myasthenia gravis or acute narrow angle glaucoma
- [Patients] History of neuroleptic malignant syndrome or active seizure disorder (with seizure episode within the past week)
- [Patients] History of Parkinson's disease, Alzheimer's or Lewy body dementia
- [Patients] History of hypersensitivity to haloperidol or lorazepam
- [Patients] History of prolonged QTc or QTcF interval (>500 ms)† if documented by most recent ECG within the past month
- [Patients] On scheduled lorazepam within the past 48 h
Where in United States
Also in 1 other country, 1 site
- M D Anderson Cancer CenterHouston, United States
- Virginia Commonwealth University/Massey Cancer CenterRichmond, United States
About the trial
What the trial wants to find out
This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care. Haloperidol and lorazepam may help in controlling symptoms of agitated delirium in patients with cancer and may lessen any distress that their caregivers may be experiencing.
The 4 groups in the trial
- Group I (haloperidol, placebo)Treatment being tested
Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
Treatment: Haloperidol, Placebo, Quality-of-Life Assessment, and Questionnaire Administration
- Group II (lorazepam, placebo)Treatment being tested
Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
Treatment: Lorazepam, Placebo, Quality-of-Life Assessment, and Questionnaire Administration
- Group III (haloperidol, lorazepam)Treatment being tested
Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.
Treatment: Haloperidol, Lorazepam, Quality-of-Life Assessment, and Questionnaire Administration
- Group IV (placebo, lorazepam)Treatment being tested
Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.
Treatment: Lorazepam, Placebo, Quality-of-Life Assessment, and Questionnaire Administration
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Strategies for Persistent Agitated Delirium in Palliative Care
- Publications
- Record updated
- 15 June 2026